Together, these data prove that the m6A modification plays an important role in regulating the tumor immune microenvironment, and the combined use of m6A modulators and PD-1/PD-L1 drugs may prove to be a new strategy to enhance the clinical efficacy of tumor immunotherapy. This evidence concerns the gene CD274 and neoplasm.